About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, September 23rd, 2015

The QualityStocks
Daily Stock List


Excel Corp. (EXCC)

Real Pennies reported on Excel Corp. (EXCC), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Excel Corp. is a top provider of integrated financial and transaction processing services to merchants throughout the U.S. Through its wholly-owned subsidiary, Securus Payments, Excel is a single source provider for almost all kinds of merchant payment processing. The Company also provides cash advance products to its merchant customers needing capital to grow. Excel has its headquarters in Irving, Texas. It maintains primary sales and merchant support offices in Portland, Oregon, and West Palm Beach, Florida. The Company lists on the OTCQB.

Excel, through Securus, operates as a national retail Independent Sales Organization (ISO) and Member Service Provider (MSP), employing its own direct sales and marketing teams and fully integrated customer relationship management (CRM) systems to promote and support its merchant customers. Excel is one of the largest ISO/MSP companies in the United States. It has in excess of 350 employees and independent sales representatives across the country.

Excel provides an array of merchant account processing solutions, together with the latest physical site and cloud based technologies. The design of these is to meet the unique needs of each industry segment it services, along with several credit, debit, gift, and loyalty card processing options and equipment to scale with the individual business needs of each client.

This past June, Excel started selling merchant cash advances under the trade name Mom and Pop Merchant Solutions (M&P). M&P is an ISO sales and management company. M&P syndicates and provides cash advances to merchants by way of its own ISO network and assorted Securus ISOs.

Recently, Excel reported consolidated results for Q2 ended June 30, 2015. Because of the Company’s acquisition of Payprotec Oregon LLC dba Securus Payments in April 2014 and limited operations before that acquisition, Excel indicates that comparative results between the 2015 and 2014 periods may not be meaningful.

Excel recorded record revenues of $4,495,430 for Q2 ended June 30, 2015. This more than doubled the revenues in Q2 of 2014. It marked a 31 percent increase in revenue from Q1 of 2015. Adjusted income from operations was $164,007 for the quarter ended June 30, 2015, versus an adjusted loss from operations of $823,448 for the quarter ended June 30, 2014 and an adjusted loss from operations of $377,248 for Q1 ended March 31, 2015. Leaving out corporate overhead, its wholly-owned subsidiary, Securus, had income from operations of $502,910 for Q2.

Excel Corp. (EXCC), closed Wednesday's trading session at $0.048, even for the day. The average volume for the last 60 days is 43,758 and the stock's 52-week low/high is $0.019/$0.081.

Premier Biomedical, Inc. (BIEI)

Innovative Marketing and SmallCapVoice reported recently on Premier Biomedical, Inc. (BIEI), and we report on the Company today, here at the QualityStocks Daily Newsletter.

El Paso, Texas headquartered, Premier Biomedical, Inc. is a research-based medical development company. Its goal is to discover and develop medical treatments, in collaboration with the University of Texas at El Paso (UTEP) and the US Department of Defense, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier Biomedical’s shares trade on the OTC Bulletin Board.

The Company is a medical development enterprise specializing in breakthroughs for serious illnesses. It has licensed the technology behind many provisional patents in the U.S. and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Premier has developed an aggressive timetable to further the development of these technologies by way of the laboratory, hospital, and clinical trials. It has started the development of potential patient trial application lists.

Premier Biomedical is initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. It announced in June 2014 that the United States Patent Office approved a patent on the Company’s proprietary medication Feldetrex ™. The design of this medication is to relieve the symptoms of neuropathic pain and fibromyalgia.

Premier Biomedical has been evaluating strategies to take its own Anti-CTLA4 breast cancer treatment through the Food and Drug Administration (FDA) approval process. The Company has several other continuing projects, in addition to its Anti-CTLA-4-based breast cancer drug. In two upcoming clinical trials, its plan is to test its Feldetrex™ pain medication, followed by a separate clinical trial of its core technology designed to remove the pathophysiological basis of the disease.

The Company has signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC", which the two entities have been developing in cooperation at the Border Biomedical Research Center, located in UTEP's $45-million Bioscience Research Building. The proprietary process strives to block a molecule called cytotoxic T-lymphocyte antigen or CTLA-4, through combining CTLA-4 blocking antibody CD152, along with Low Dose Metronomic Chemotherapy. Important progress has been made over the past year advancing the development of CD152-LDMC.

In August, Premier Biomedical announced the addition of Dr. Carl E. Meyer and his wife, Dr. Kathryn R. Meyer to their Scientific Advisory Board. Dr. Meyer will report to the Co-Founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD, and to the President and Chief Executive Officer, Mr. William A. Hartman. Dr. Carl E. Meyer, DO, MBA, is a pediatrician and a Fellow of the American Academy of Pediatrics. Dr. Kathryn R. Meyer, DO, is an Emergency Physician, certified by the American Academy of Osteopathic Emergency Physicians. She is presently Medical Director of the University of Pennsylvania Medical Center (UPMC) Hermitage Urgent Care Center in Hermitage, Pennsylvania.

Premier Biomedical, Inc. (BIEI), closed Wednesday's trading session at $0.019, up 40.74%, on 17,027 volume with 3 trades. The average volume for the last 60 days is 82,986 and the stock's 52-week low/high is $0.0123/$0.33.

Communication Intelligence Corp. (CICI)

SmallCapVoice, TheMicrocapNews, PennyTrader Publisher, Top Gun, and The Stock Psycho reported previously on Communication Intelligence Corp. (CICI), and we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

Communication Intelligence Corp. (CIC) is a top supplier of electronic signature products and the recognized leader in biometric signature verification. The Company enables enterprises to realize truly paperless workflow in their electronic business processes. It does so through providing multiple signature technologies across almost all enterprise, desktop, and mobile environments as a seamlessly integrated platform for ad-hoc and fully automated transactions. CIC has its corporate headquarters in Redwood Shores, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

In essence, CIC is a leading supplier of electronic signature and other software solutions. These enable secure and cost-effective management of document-based digital transactions. The Company’s solutions cover a wide variety of functionality and services. These include electronic signatures, biometric authentication, and simple-to-complex workflow management. CIC's platform can be deployed both on-premise and as a cloud-based service. The platform can easily transition between deployment models.

CIC provides digital transaction management (DTM) software allowing for fully digital business processes.  So far, it has primarily delivered biometric and electronic signature solutions to channel partners and end-user customers in the financial services industry.

The Company’s solutions are available in Software-as-a-Service (SaaS) and on-premise delivery models. Its solutions provide "straight-through-processing." This has the ability to grow customer revenue through enhancing user experience. Moreover, CIC’s solutions can reduce costs through paperless and virtually error-free electronic transactions, which can be completed considerably faster than paper-based procedures.

In August, CIC reported revenue of $367,000 for the three months ended June 30, 2015. This represents a decrease of $106,000 or 22 percent, versus total revenue of $473,000 for the same quarter in the year prior. For the six months ended June 30, 2015, total revenue was $814,000. This represents an increase of $40,000, or 5 percent, versus total revenue of $774,000 for the same period in the year prior.

Communication Intelligence Corp. (CICI), closed Wednesday's trading session at $0.0065, even for the day, on 1,032 volume with 2 trades. The average volume for the last 60 days is 35,772 and the stock's 52-week low/high is $0.0045/$0.0346.

Optex Systems Holdings, Inc. (OPXS)

Epic Stock Picks, Wallstreetlivechat, and Pumps and Dumps reported earlier on Optex Systems Holdings, Inc. (OPXS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Optex Systems Holdings, Inc. is a foremost manufacturer of optical sighting systems and assemblies chiefly for Department of Defense (DoD) applications. The Company also manufactures and delivers numerous periscope configurations, rifle and surveillance sights, and night vision optical assemblies. It delivers its products directly to the military services and to prime contractors. Optex Systems, Inc. is a wholly-owned subsidiary of Richardson, Texas-based Optex Systems Holdings.

The Company’s products are installed on diverse types of U.S. military land vehicles. These include the Abrams and Bradley fighting vehicles, Light Armored, and Armored Security Vehicles. Additionally, its products have been selected for installation on the Stryker family of vehicles.

Optex Systems manufactures the US Navy 20x 120mm Ship Binoculars and also brings creative technology to vehicular mounted sighting systems. The Company’s dismounted sighting systems work on weapon sights, night vision goggles, and any other sighting requirements outside of ships and land vehicles. Optex Systems can also meet Commercial (non-military) requirements.    

Optex Systems’ products include its Laser Protected Periscopes. The Optex periscopes come with optional laser protection in both glass and plastic. This is to protect soldiers’ eyes as they do battle from different vehicle platforms. These platforms include the Bradley, Stryker Family, and the M60 tank varieties. The Company’s products also include the Muzzle Reference Sensor. It allows for consistent accuracy during repeated fire by calibrating the tank barrel to the sighting system. Optex sensors are used in the Abrams A1, A2, Korean K1, and the Stryker Main Gun System.

Furthermore, Optex Systems’ products include its DDAN/M36 Sights. It allows soldiers safer and more efficient field performance with the user-friendly digital displays and optional laser protection. The Company’s M36E3 combines day and night sights into one smaller device that easily adjusts to any change in lighting.

Optex Systems Holdings reported (in November 2014) the completion of the acquisition of Applied Optics Center (AOC) Division of Warrior Systems Sector with the Electronics Systems Business Segment of L-3 Communications Corp.

In June 2015, Optex Systems, Inc., the wholly-owned subsidiary of Optex Systems Holdings, announced that it was awarded 11,200 ACOG Laser Filter Units valued at $1.3M. This award resulted from a successful proposal supplied through the earlier acquired Applied Optics Center (AOC) Division. It includes an option quantity up-to an additional 11,200 units for a potential contract value of $2.6M.

Optex Systems Holdings, Inc. (OPXS), closed Wednesday's trading session at $0.0076, even for the day. The average volume for the last 60 days is 126,749 and the stock's 52-week low/high is $0.0036/$0.03.


Innovative Marketing, Zacks, TopPennyStockMovers, BabyBulls, and SmallCapVoice reported earlier on ULURU, Inc. (ULUR), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

ULURU, Inc. is a specialty pharmaceutical company concentrating on the development of a portfolio of wound management and oral care products. This is to provide patients and consumers improved clinical outcomes through controlled delivery using the Company’s innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. ULURU is headquartered in Addison, Texas.

The Company’s business strategy is to develop and commercialize a customer-focused portfolio of inventive wound care products to treat the different phases of wound healing. Furthermore, ULURU’s strategy involves developing the oral-transmucosal technology and generating revenues via many licensing agreements.

Its products include Altrazeal®. ULURU developed and commercializes Altrazeal® - a transforming powder dressing with proprietary Nanoflex® technology, for the management of exuding wounds. Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing.

ULURU announced this past May that it would be acquiring the 75 percent ownership of Altrazeal Trading GmbH not now owned by the Company.  It was granted the option pursuant to a Shareholders Agreement dated January 11, 2012, to acquire the remaining ownership for a predetermined valuation.

Altrazeal® has demonstrated potential clinical and economic advantages in several chronic and acute wounds. These include diabetic foot ulcers, venous leg ulcers, and geriatric wounds. Altrazeal® has now been launched onto the German market. ULURU was also advised by the Chinese patent office that the patent covering Altrazeal® has been issued. This further expands the extensive world-wide patent protection ULURU has attained for Altrazeal®.
ULURU’s products also include Aphthasol®. It contains 5% amlexanox in an adhesive oral paste. Aphthasol® is Food and Drug Administration (FDA) approved and indicated for the treatment of aphthous ulcers in people with normal immune systems.

ULURU also has its OraDisc™A. It developed OraDisc™ A, a novel mucoadhesive, water-erodible disc incorporating 2mg of amlexanox, for the treatment and prevention of aphthous ulcers. Its OraDisc™ B is a mucoadhesive erodible disc containing 15 mg of benzocaine, which has undergone development for the treatment of oral pain.

Additionally, the Company developed a unique, patented delivery strip for whitening teeth which totally erodes (OraDisc™ W- Erodible Whitening Strip for Teeth). Its proprietary tooth whitening product consists of a laminated bilayer strip that utilizes the OraDisc™ technology.

Recently, ULURU has reported positive interim data for the pharmaco-economic evaluation being conducted in Europe; received marketing approval in Russia for the sale of Altrazeal®; shipped the first order of Altrazeal® for Egypt and the first partial order of Altrazeal® for Saudi Arabia; as well as shipped the first commercial quantity order of Altrazeal® for Croatia.

ULURU, Inc. (ULUR), closed Wednesday's trading session at $0.30, even for the day, on 1,000 volume with 1 trade. The average volume for the last 60 days is 19,252 and the stock's 52-week low/high is $0.235/$1.19.


The QualityStocks
Company Corner


Fastfunds Financial Corp. (FFFC)

The QualityStocks Daily Newsletter would like to spotlight Fastfunds Financial Corp. (FFFC). Today, Fastfunds Financial Corp. closed trading at $0.0002, even for the day, on 74,187,609 volume with 31 trades. The stock’s average daily volume over the past 60 days is 26,937,915, and its 52-week low/high is $0.0001/$0.12.

Fastfunds Financial Corp. announced today that it has relaunched the Tommy Chong Green Card website (www.TommyChongGreenCard.com) with enhanced features that coordinates and achieves consistency among all of the Companys marketing materials. The Company is also finalizing plans for the launch of a social media integration program developed by media consultant Casa Giallo, Inc. Building on the relaunched website, the purpose of this program will be to create via social media a widespread awareness regarding the Tommy Chong Green Card by integrating the various social media streams of Tommy Chong that combine for over 4 million followers. The target date for this launch is early October and the Company will provide further details at that time. Casa Giallo, Inc. has positioned itself as an industry leader in the cannabis space working with clients such as Snoop Dogg and Tommy Chong among others.

Fastfunds Financial Corp. (FFFC) operates through two wholly owned subsidiaries, Cannabis Angel, Inc. and The 420 Development Corporation, to build a portfolio of revenue-generating companies that provide ancillary services to the burgeoning cannabis industry. The company also operates majority-owned subsidiary Financiera Moderna, Inc., which offers financial services to the underserved Hispanic community. FFFC's strategy to participate in the marijuana industry is through the development of four separate business verticals for the emerging U.S. cannabis industry.

Through its 49% stake in Cannabis Merchant Financial Solutions, Inc. (CMFS), FFFC entered the Financial Service business vertical. CMFS developed the Green Card and Tommy Chong Green Card, a reloadable stored value card with a rewards feature, and the Tommy Chong Frequent Buyers Card, which functions as a gift card or rewards card. FFFC is developing a national group of master resellers, distributors and sales representatives for these card products.

As the cannabis industry continues to develop, FFFC is partaking in Plant Botany, specifically the development of methods and technologies to significantly enhance plant growth and purity. Under an operating agreement with Sanidor Systems to create Pure Grow Systems, LLC, FFFC acquired a 49% interest in the subsidiary, which is dedicated to the healthy production and processing of raw materials used for medicinal or other health related purposes.

The cannabis industry is a cash-only business, which leaves companies vulnerable to criminal activities. FFFC plans to address this issue and enter the Security Services and Equipment sector through the acquisition of an existing, operational security company. FFFC owns a 70% stake in Ohio-based Brawnstone Security, Inc., a diversified security, training and investigations company. FFFC's research shows that operating margins for cannabis-related security services could exceed current billing levels by at least 100%.

FFFC's Cannabis Angel, Inc. ("CA") subsidiary will evaluate and provide corporate development services and early seed financing for worthwhile development-stage cannabis ventures. To date, CA has made investments in companies involved in the distribution of cannabis-related products and development of a social media website. It is important to note that all of FFFCs activities in the cannabis industry are ancillary, or pick and shovel, and are evaluated to insure compliance with all state and federal Laws. Disclaimer

Fastfunds Financial Corp. Company Blog

Fastfunds Financial Corp. News:

Fastfunds Financial Corporation Announces Relaunch Of Enhanced Tommy Chong Green Card Website And Plans To Launch Social Media Integration Program

Fastfunds Financial Corporation Provides Update for Subsidiary Brawnstone Security

Fastfunds Financial Corporation Announces Significant Marketing Progress for Subsidiary Pure Grow Systems One-Step Disinfectant Cleaner

Star Mountain Resources, Inc. (SMRS)

The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $1.10, up 15.79%, on 6,500 volume with 6 trades. The stock’s average daily volume over the past 60 days is 4,189, and its 52-week low/high is $0.50/$1.40.

Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.

Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.

The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.

Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer

Star Mountain Resources, Inc. Company Blog

Star Mountain Resources, Inc. News:

Star Mountain Resources Inc. (SMRS) Pursues Acquisition Opportunities in North American Mining Sector

Star Mountain Resources Inc. Pursuing Acquisition of North American Base Metal Mine

StockNewsNow.com Publishes New SNN Q&A with Star Mountain Resources Inc.

Avant Diagnostics, Inc. (AVDX)

The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.25, up 8.70%, on 916 volume with 4 trades. The stock’s average daily volume over the past 60 days is 2,243, and its 52-week low/high is $0.2003/$1.95.

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer

Avant Diagnostics, Inc. Company Blog

Avant Diagnostics, Inc. News:

Avant Diagnostics Inc. Engages Goal Capital Inc. to Provide Investor Relations Services

Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm

Avant Diagnostics, Inc. Retains Sichenzia Ross Freidman Ference LLP as Its Corporate Counsel

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $4.05, up 8.00%, on 28,807 volume with 102 trades. The stock’s average daily volume over the past 60 days is 2,868, and its 52-week low/high is $1.25/$18.15.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Names Ms. Ebrahimi as Chief Financial Officer

International Stem Cell Corporation Announces Next Phase of Research Collaboration With Rohto Pharmaceutical Co., Ltd. of Japan

International Stem Cell Corporation to Present at the Rodman and Renshaw Global Investment Conference

Growblox Sciences, Inc. (GBLX)

The QualityStocks Daily Newsletter would like to spotlight Growblox Sciences, Inc. (GBLX). Today, Growblox Sciences, Inc. closed trading at $0.3399, up 6.22%, on 57,873 volume with 14 trades. The stock’s average daily volume over the past 60 days is 62,666, and its 52-week low/high is $0.151/$1.51.

Growblox Sciences, Inc. (GBLX), a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant's life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, Growblox Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, Growblox Sciences has positioned itself well for long-term success in the burgeoning cannabis space. Disclaimer

Growblox Sciences, Inc. Company Blog

Growblox Sciences, Inc. News:

GrowBLOX Sciences Secures Four New Nevada State Medical Cannabis Licenses

GrowBLOX Sciences Appoints Former Nevada State Senator Sandra Tiffany as New General Manager

GrowBLOX Sciences Appoints New CFO John Poss


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



INO.com Market Report





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251